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BACKGROUND Osteoporosis Australia has been committed to the education of general practitioners and the
community with a series of updated guidelines on the management of osteoporosis. Since the last series was published
in Australian Family Physician (August 2000), there have been further advances in our understanding of the
treatments involved in both prevention of bone loss and the management of established osteoporosis.
OBJECTIVE This article represents updated guidelines for the treatment of postmenopausal osteoporosis to assist GPs
identify those women at risk and to review current treatment strategies. 
DISCUSSION Osteoporosis and its associated problems are major health concerns in Australia, especially with an aging
population. While important principles of management are still considered to be maximising peak bone mass and
preventing postmenopausal bone loss, new clinical trial data about drugs such as the bisphosphonates, 
raloxifene and oestrogen have recently become available and the relative role of various agents is gradually becoming
clearer. The use of long term hormone replacement therapy has mixed risks and benefits that requires individual
patient counselling. 
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Osteoporosis is defined as a skeletaldisorder characterised by low
bone mass and microarchitectural dete-
rioration of bone tissue, leading to an
increase in bone fragility and suscepti-
bility to fracture.1,2 Clinically,
osteoporosis is synonymous with low
bone density. An osteoporotic fracture
is one that occurs with minimal or no
trauma, ie. a fall from standing height
or less. 
Although it is generally recommended
that interventions are appropriate for
women with bone densities more than 2.5
standard deviation (SD) units below the
young normal mean (T-score <-2.5), pre-
ventive measures should be considered
before that level is reached. Accordingly,
the following intervention guidelines are
suggested (Figure 1):
• consider preventive measures in post-
menopausal women with significant
osteopenia, ie. bone mineral density
(BMD) values less than 2.0 SD below
the young normal mean (T-score
between -2.0 and -2.5) as osteoporosis
is likely with time. As mildly
osteopenic women (T-score between -
1.0 and -2.0) aged 50-60 years have a
low absolute risk of fracture, it is diffi-
cult to justify treatment for potentially
large numbers of women3 
• strongly recommend treatment in post-
menopausal women with osteoporosis,
ie. BMD values less than 2.5 SD below
the young normal mean (T-score 




Although medical intervention may be
required in some individuals, patients
should understand that it is important to:
• maximise peak bone density in child-
hood and adolescence




• promote a diet with adequate calcium
content and advocate regular weight
bearing exercise in children and ado-
lescents
• exercise in women over the age of 30
years should include resistance training
to improve muscle mass, strength and
balance and should be performed
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Reassure and follow up in 
2-5 years unless secondary







• Raloxifene or HRT
• Etidronate 
* There are no data that intervention in women with mild to moderate osteopenia (T-score -1.0 to -2.0), in the absence of a
prevalent fracture, is beneficial in reducing the risk of subsequent osteoporotic fractures. Therapy aimed at prevention of bone
loss may however, be warranted in some clinical situations. The imperative to consider intervention increases as the T-score
decreases.
T-score >-1
T-score -2 to -2.5
T-score <-2.5
Figure 1. Intervention guidelines
three times per week3
• encourage good general nutrition and
ensure that vitamin D status is main-
tained especially in elderly patients 
• discourage tobacco use.
The risk of developing osteoporosis is
increased by certain factors (Table 1) and
by some medical conditions (Table 2).
Although lifestyle prevention mea-
sures are important, pharmaceutical
agents may be recommended for the pre-
vention of postmenopausal bone loss.
Randomised trials have shown beneficial
effects of potent bisphosphonates, selec-
tive oestrogen receptor modulators,
oestrogen and tibolone in prevention of
postmenopausal bone loss.4-7 These agents
are discussed in more detail later. 
Diagnosis
Dual energy X-ray absorptiometry 
Dual energy X-ray absorptiometry
(DXA) measures a patient’s BMD,
enabling fracture risk prediction. Dual
energy X-ray absorptiometry is the gold
standard for osteoporosis diagnosis, as it
is reliable with a reported precision of
approximately 1-1.5% at the spine and
approximately 3% at the proximal femur.
In day-to-day practice, compared with
research studies, precision may be some-
what less. Postmenopausal women lose
bone density at a rate of approximately 
1-2% per year therefore biennial scans
are generally adequate. In patients who
are likely to have increased bone loss (eg.
glucocorticoid treatment), more frequent
scans may be indicated.3
Bone mineral density is expressed in
terms of a T-score, which represents the
number of SD from the young normal
mean BMD (Figure 2). For every one SD
decrease in BMD the relative risk of frac-
ture increases 1.5-2.5-fold. Vertebral
fracture risk is increased by a factor of 2.3
(range 1.9-2.8) for each SD reduction in
lumbar spine BMD.8 Currently, total hip
BMD is most commonly used to predict
overall fracture risk, as proximal femoral
measurements are less affected by
osteoarthritis, which can falsely elevate
spine BMD values.3 The Z-score is the
number of SDs from population mean for
age (ie. age matched). 
Biochemical markers of bone
remodelling
Serial biochemical markers of bone
turnover can be measured in serum and
urine, and may provide additional infor-
mation for assessing fracture risk.
Increased bone turnover markers in the
presence of a low BMD would favour
treatment of the patient. Additionally,
markers may be used to assess the
response to treatment and thus increase
therapy adherence.3
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Table 1. Factors associated with increased risk of osteoporosis
• Increasing age
• Menopause (especially premature)
• Family history of osteoporosis
• Previous low trauma fracture
• Medical conditions (Table 2)
• Low calcium intake
• Low body weight (defined as BMI <20)
• Eating disorders associated with decreased weight
• Immobilisation
• Lifestyle factors including smoking, alcoholism, lack of exercise or excessive exercise
Table 2. Medical conditions associated with increased risk of
osteoporosis
• Prolonged glucocorticoid therapy
• Conditions associated with excess glucocorticoid secretion
• Amenorrhoea lasting more than six months before the age of 45 years
• Primary hyperparathyroidism
• Chronic liver disease
• Chronic renal disease
• Malabsorption
• Rheumatoid arthritis
• Conditions associated with thyroxine excess
NB: A Medicare rebate is available for bone densitometry in these situations.
Figure 2. WHO definitions of low bone density using DXA 
T-score >-1
T-score between -1 to -2.5
T-score <-2.5






Although osteoporosis is a common con-
dition, a cause should be identified if
possible and the specific disease processes
treated appropriately. Investigations are
usually normal, but are indicated to
exclude other specific medical conditions
(Table 2), especially where the Z-score is
less than -1.5 on bone densitometry.
Typical investigations might include:
• a full blood count (FBC)
• erythrocyte sedimentation rate (ESR)
• calcium
• creatinine
• total alkaline phosphatase and albumin
• thyroid stimulating hormone (TSH)
• protein electrophoresis (EPP)
• anti-endomysial antibody
• parathyroid hormone (PTH)
• 25 hydroxy vitamin D. 
All patients aged 45 years and older sus-
taining a low trauma fracture should be
considered for bone densitometry
because of the high likelihood of having
osteopenia/osteoporosis.
General measures
These include recommendations for
lifestyle modification discussed earlier
and fall prevention measures, which may
be beneficial and prevent fractures. The
optimal use of exercise relies upon deliv-
ery of a sustained adequate dose of the
correct modality of exercise to the target




Bisphosphonates are potent inhibitors of
bone resorption. Currently three bisphos-
phonates (alendronate, risedronate and
etidronate) are approved in Australia on
the PBS (Authority required) for the
treatment of established osteoporosis in
postmenopausal women with fracture due
to minimal trauma. Alendronate and rise-
dronate have been reported to reduce the
risk of single, multiple and morphometric
(asymptomatic) vertebral fractures in
women with osteoporosis and one or
more baseline vertebral fractures.9-12
Alendronate and risedronate have also
been reported to reduce the risk of verte-
bral fractures by 50% in women who have
osteoporosis without a pre-existing verte-
bral fracture.13,14 The risk reduction with
potent bisphosphonates is usually seen
within the first 6-12 months. Peripheral
fracture rates are also reduced with alen-
dronate and risedronate in patients with a
prevalent vertebral fracture. Data for
antihip fracture efficacy are also avail-
able. In the alendronate trials, there was
consistency in hip fracture risk reduction
but hip fracture was not a primary end-
point.10,13 In one risedronate trial, in which
hip fractures were the primary endpoint,
there was a 40% reduction in hip fracture
risk among women aged 70-79 years with
osteoporosis confirmed on DXA (base-
line T-score <-3).15
The use of alendronate and rise-
dronate has been associated with
dyspepsia, abdominal pain and
oesophageal ulceration and should be
prescribed with caution in patients with a
history of reflux oesophagitis or hiatus
hernia.16 However, the overall risk of gas-
trointestinal events with alendronate and
risedronate is very low (see Case history),
and weekly bisphosphonates may further
reduce the risk of this side effect.17
Etidronate is used in a cyclical
regimen for osteoporosis, usually for two
weeks every three months, because it can
result in mineral defects if used continu-
ously. A number of smaller controlled
trials with etidronate show increases in
bone density averaging 5% over 2-3
years18 and suggest a 50% reduction in
vertebral fracture rate. Etidronate has
been associated with lower, but not
upper, gastrointestinal events.19 There
appears to be no risk of mineralisation
defect with the cyclical regimen.18
Bisphosphonates are polar (water
soluble) drugs and when taken orally, the
bioavailability is low (<1%). Calcium
should not be taken at the same time of
day as a bisphosphonate, since it inter-
feres with their absorption.
Bisphosphonates should also be taken
least 30 minutes before meals to allow
adequate absorption. 
The increase in BMD that occurs with
prolonged use of bisphosphonates (more
five years) is maintained for 2-3 years
after cessation. This does not occur with
hormone replacement therapy (HRT),




Raloxifene is a selective oestrogen recep-
tor modulator (SERM), which acts to
decrease bone resorption, like oestrogen,
but without stimulating the breast or
uterus. Lipid profiles are improved and
breast cancer incidence has been reported
to be reduced by 60-70% over four
years.21 Controlled clinical trials with
raloxifene have shown modest increases
in bone density, although this is generally
somewhat less than that seen with bispho-
sphonates or oestrogen. In women with
prevalent vertebral fractures, a 36%
reduction in vertebral fractures was noted
using a dose of 60 mg/day for four years.
In women without prevalent vertebral
fractures, the relevant risk reduction is
greater (55%). Peripheral fractures were
not reduced, for reasons that are
unclear.22 An increased risk of deep
venous thrombosis has been reported
with raloxifene users similar to that seen
with HRT users. Treatment should be
ceased if patients are immobilised for any
prolonged period. Unlike HRT, ralox-
ifene is not useful for control of, and may
worsen, menopausal symptoms.
Raloxifene is available on the PBS
(Authority required) for established post-
menopausal osteoporosis in patients with
fracture due to minimal trauma.
Raloxifene has also been shown to be
effective for prevention of post-
menopausal bone loss and should be
considered as an alternative in women
unable to take oestrogen for this indica-
tion (no PBS listing for this purpose).
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Hormone replacement
therapy
The role of long term HRT in the preven-
tion and management of osteoporosis
remains controversial following the results
of the Women’s Health Initiative (WHI)
study of combined HRT. This study was
ceased prematurely in May 2002 because of
an increase in breast cancer of eight per 10
000 women years. However, this was bal-
anced by a similar reduction in other major
cancers such as bowel cancer. A possible
increased cardiovascular risk was also seen
in the WHI cohort, many of who had pre-
established cardiovascular disease risk
factors.23 The Therapeutic Goods
Administration expert committee report
concluded that the continued use of com-
bined HRT for women with established
osteoporosis is an acceptable option for
many, but women should discuss the bene-
fits and risks with their treating doctors.
The committee also recommended a full
review of the use of combined HRT in long
term treatment and prevention of osteo-
porosis.24
Although oestrogen is effective in pre-
venting loss of bone density when given at
or near menopause, it is also effective in
reducing loss of bone density over 10-15
years after menopause, with increases in
bone density averaging 5% over three
years.7 The WHI cohort experienced
lower hip fracture rates (10 per 10 000
person years in the oestrogen and prog-
estin group (E + P) versus 15 per 10 000
person years in the placebo group).
Oestrogen and progestin treatment led to
statistically significant reductions in frac-
ture rates compared with placebo for hip
and clinical vertebral fracture rates, other
osteoporotic fractures and total frac-
tures.23
The data relating to increased risk of
breast cancer with long term HRT use
from observational studies remains incon-
clusive. Some studies have shown an
increased relative risk of breast cancer of
up to 1.5 in long term HRT users, other
studies show minimal or no increase in
risk.25 In the WHI study with combined
HRT the invasive breast cancer rate
showed a hazard ratio (adjusted 95% CI)
of 1.26 (0.83-1.92). This rate reached the
(conservative) predetermined cut off
point in the trial protocol for breast
cancer and the combined HRT arm of the
trial ceased. The risk found, to that point,
was half the increased risk (RR: 1.53) pre-
dicted in the Lancet re-analysis of
observational studies by Beral et al26 for
combined HRT preparations. The
absolute increase seen in the WHI data
was 38 versus 30 cases per 10 000 women
years commencing only after four years.
No significant difference was observed for
in situ breast cancers. There were no dif-
ferences in mortality or cause of death
between the groups.23
A parallel trial of the WHI investigat-
ing oestrogen alone in women who have
had a hysterectomy is being continued.
The NIH states there is currently no evi-
dence of increased risk of breast cancer in
the oestrogen only arm of the WHI study
although data from this arm is not yet
available. This is planned to be complete
in 2005 with an average follow up of 8.5
years. If the same significant reduction in
hip and vertebral fractures is seen in that
arm without significant breast cancer risk
then the risk/benefit ratio for oestrogen
alone therapy in hysterectomised women
may appear favourable at the end of the
trial, although the effects on cardiovascu-
lar disease will also need to be
considered.23 In a similar but larger, long
term HRT study, The Women’s
International Study of Long Duration
Oestrogen after Menopause (WISDOM)
(conducted in the United Kingdom, New
Zealand and Australia) the Data
Monitoring Committee and the WISDOM
Steering Committee have recommended
that it is ethical and scientifically valid to
continue. Until the data becomes conclu-
sive caution is needed; for each individual
patient the potential benefits must be
rationally considered against the possible
small increase in risk.
Ideally, oestrogen therapy should be
continuous (ie. without a break in
therapy). Adjuvant progestogens are nec-
essary in women who still have a uterus,
to protect against endometrial cancer.
They may be given cyclically for 10-14
days each month in perimenopausal
women or as continuous therapy com-
bined with oestrogen in postmenopausal
women. The latter is more suitable for
women more than two years post-
menopause to avoid the initial irregular
bleeding, normally seen with this
regimen, being unduly prolonged.
The minimum effective dose of oestro-
gen therapy has yet to be clearly
established, but many routes of adminis-
tration can achieve the beneficial effects
of oestrogen therapy and lower doses can
be used in combination with calcium sup-
plements especially in elderly women.
The optimal dose of oestrogen therapy
required to prevent perimenopausal
BMD loss may vary from woman to
woman. As with any therapy for osteo-
porosis, repeat bone density should be
considered after two years to check that
the therapeutic regimen is efficacious.27
Calcium
Calcium is weakly antiresorptive and sup-
plementation may reduce negative
calcium balance, especially in older age.
Most studies suggest the required daily
intake is between 1000 mg and 1500 mg in
postmenopausal women not taking
oestrogen replacement therapy. This can
be obtained from dairy products. For
example, an average glass (250 mL) of
milk contains 300 mg of calcium, two
slices (40 g) of cheddar cheese contains
300 mg of calcium and one tub (200 g) of
yoghurt contains 340 mg of calcium. For
those who are unable to tolerate dairy
products, calcium enriched soy milk and a
large variety of calcium supplements are
currently available from pharmacies and
health food stores. However, patients
need to understand the varying calcium
content of different supplements and that
the recommended daily intake relates to
elemental calcium. Controlled trials have
found small effects of calcium on bone
Guidelines for the treatment of postmenopausal osteoporosis for general practitioners  n
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density averaging 1-2%, associated with a
modest reduction in fracture risk in some
studies.28,29 
In patients using bisphosphonates,
calcium must not be taken at the same
time of day as the bisphosphonate or the
calcium will impair absorption of the
drug. Calcium may also cause mild consti-
pation or upper gastrointestinal upset. It
should be avoided in patients with a
history of renal calculi in the presence of
hypercalciuria. Calcium citrate is now
available in Australia as an option for
these patients. 
Vitamin D 
Vitamin D undergoes metabolism in the
liver and kidney. Simple vitamin D is
mainly available in Australia as ergocal-
ciferol (Ostelin 1000 IU per capsule) or
cod liver oil tablets (approximately 400
IU). Smaller amounts of vitamin D are
also contained in some calcium and
vitamin supplements (eg. Caltrate + D
contains 200 IU per tablet). One French
study involving largely vitamin D defi-
cient institutionalised elderly patients,
showed simple vitamin D, when used with
calcium supplements, reduced hip frac-
tures.30 In Australian populations with
limited exposure to sunlight (eg. the
housebound elderly, the institutionalised,
dark skinned or veiled women) subclini-
cal vitamin D deficiency and osteomalacia
are also common. Accordingly, long term
vitamin D supplementation (1000 IU/day)
is recommended in patients with a poor
diet or limited sunlight exposure. 
Since several of the controlled trials of
antiresorptive agents previously described
have used concomitant calcium and
vitamin D, it is appropriate to add a
calcium supplement to most therapies,
except calcitriol.
Calcitriol (active vitamin D
metabolite)
Calcitriol has a therapeutic profile distinct
from vitamin D, and should not be used
in the treatment of vitamin D deficiency.31
Calcitriol is available on the PBS
(Authority required) for the treatment of
postmenopausal osteoporosis. The evi-
dence on efficacy in fracture prevention is
confusing with studies showing both
increased and decreased numbers of frac-
tures.3 Calcitriol should not be used as a
sole therapy for the treatment of osteo-
porosis. 
Parathyroid hormone
Parathyroid hormone (PTH) stimulates
osteoclasts and osteoblasts in the bone,
however, when presented to bone inter-
mittently, such as in daily subcutaneous
administration, it has a net anabolic
action. Its major action is to prevent
osteoblast apoptosis and thereby prolong-
ing the bone formation cycle. Parathyroid
hormone increases the uptake of calcium
from the gut and reduces its excretion in
the kidney. It reduces the relative risk of
vertebral fractures (up to 65% in women
with osteoporosis and one or more base-
line fractures) as well as peripheral
fractures. When it becomes available in
Australia, PTH is anticipated to become a
treatment option in severe osteoporosis
due to its bone structure modulation.32
Monitoring therapy
After therapy has been initiated, it is
important to monitor patients to ensure
that bone loss is controlled. Bone densito-
metry using DXA measurements can be
used for monitoring the efficacy of
therapy because of their excellent preci-
sion, and they can be performed rapidly
and conveniently. It should be noted, that
changes of less than 5% are within the
precision error of most machines and
therefore should be regarded as repre-
senting no significant change. It is often
recommended that a repeat DXA be per-
formed within one year of commencing
osteoporosis treatment. However, a mea-
surement at two years is likely to be a
more accurate representation of the
effects of an antiresorptive drug.
Thereafter, biennial DXA assessments
are usually carried out to monitor
response to therapy. Repeat measure-
ments should generally be performed on
the same machine for monitoring, assum-
ing the DXA provider has good quality
control with acceptable precision error.
Biochemical measures of bone turnover
may become useful in the management of
the individual patient but their role has
yet to be established. In certain instances
a referral to a specialist may be able to
fine tune therapy (Table 3).
Preventing falls
Interventions to reduce the risk of falling
include:
• modifying the environment to reduce
the risk of slipping and tripping by
eliminating slippery surfaces, loose
rugs, narrow passageways, dangerous
furniture. Most people report trips,
slips and loss of balance as the cause of
the fall, whereas only a small propor-
tion report dizziness or feeling faint
• modifying living habits:
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Table 3. When to consider referral to a specialist
Referral to specialist bone centres is appropriate in the following circumstances:
• When patients experience problems or side effects with treatment
• When patients have other complex medical conditions
• When GPs do not have access to appropriate bone densitometry
• When patients show inadequate response to therapy
• When patients have a vertebral fracture - a one visit assessment by a specialist is
prudent
• When young patients (age <50) have osteoporosis
• When a secondary cause is identified
• Patients who continue to fracture with ‘normal’ bone densitometry
- by wearing appropriate footwear
- taking care when walking up or down
steps, especially if patients wear 
bifocals
- taking care at night and in poorly lit
conditions
• installing appropriate aids (eg. using
supportive hand rests, rails and nonslip
bathmats)
• modifying medications such as seda-
tives or certain antihypertensives that
might predispose patients to falls
• correcting poor vision 
• involving community agencies to:
- provide support services to help
implement the modifications
required to reduce risk of injury
- ensure nursing and physiotherapy
services are provided when needed.
Specific exercise programs that emphasise
muscle strengthening and balance retrain-
ing (eg. Tai Chi) may also be effective.33
Where to get more help
Most states and territories have branches
of support services for people with
medical conditions, including osteoporo-
sis (Table 4).
Conclusion
The management of postmenopausal
osteoporosis should be based on an indi-
vidual risk/benefit analysis, time since
menopause, presence or absence of
oestrogen withdrawal symptoms, history
of traumatic fractures and other medical
conditions.
Oestrogen therapy remains appropri-
ate for women at the time of menopause
for those with symptoms, those with a
premature menopause or surgical
menopause. The duration of use should
be reviewed with each woman after 2-5
years. Tibolone is an alternative to
oestrogen therapy, and its effect on BMD
appears to be similar (however, there are
no antifracture data available). 
Raloxifene and bisphosphonates are
alternatives for prevention of bone loss
after the menopause when symptoms of
oestrogen withdrawal are no longer a
consideration, although their use in this
fashion before a fracture is currently not
subsidised by the PBS. 
In older women especially those with
a previous osteoporotic fracture and high
risk of further fracture, bisphosphonates
should be considered as first line therapy
because they prevent both nonvertebral
and vertebral fractures. 
All women should have an adequate
calcium intake. Simple vitamin D supple-
mentation should be considered in those
groups at risk of vitamin D deficiency and
osteomalacia, either as monotherapy or in
combination with other treatments.
Case history
A 72 year old women presents following a
fall, in which she sustained a forearm frac-
ture. Her risk factors for osteoporosis
include a positive family history, use of
inhaled corticosteroids for airways disease
and an early menopause at 45 years of age.
Bone densitometry confirms a low spine
and hip T-score of -2.6 and -3.0 respec-
tively. Her sister died of breast cancer at
the age of 60 years. She suffers from mild
dyspepsia, for which she takes antacids.
The first treatment choice in this
woman, who has so called ‘established’
osteoporosis, based upon her previous
fracture, is between the bisphosphonates
Guidelines for the treatment of postmenopausal osteoporosis for general practitioners  n
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Table 4. Osteoporosis support services available in Australia
• Osteoporosis Australia: Osteoporosis Australia has a range of education materials
available for patients and healthcare professionals, which cover different aspects of
osteoporosis and its management. There are regular courses on osteoporosis and
self management to teach people how to maintain bone mass, avoid falls and
fractures, and live more comfortably with osteoporosis.
Helpline 1800 242 141
Website: www.osteoporosis.org.au 
• State affiliates of Osteoporosis Australia 
• Specialist colleagues with an interest in osteoporosis
• Teaching hospitals 
• Services for people with a disability (community help and welfare services)
• Community home care services
• The cause of osteoporosis should
always be defined and specific
disease processes should be treated
appropriately.
• Whereas primary prevention of
fracture remains crucial, treatment
to ensure further fractures do not
occur is equally as important.
• Any patient aged 45 years and older
presenting with a low trauma
fracture should undergo bone
densitometry (Medicare rebate
available for these patients). 
• Women at high risk of osteoporosis
(Table 1, 2) should undergo DXA for
diagnosis (although only Table 2
attract a Medicare rebate). 
• The role of long term oestrogen as
first line therapy to prevent bone
loss at the time of menopause is
controversial. The potential benefits
must be rationally considered and
discussed with patients, balanced
against the possible small increased
risk of breast cancer. 
• In older patients with previous
fractures, the rank order of
treatments is alendronate or
risedronate, followed by raloxifene
and then etidronate. 
• Simple vitamin D should be
considered in the housebound or
institutionalised elderly. 
• Lifestyle changes relating to dietary
calcium, the correct modality of
exercise and fall prevention are also
important. 
S U M M A R Y  O F  
I M P O R T A N T  P O I N T S
(alendronate or risedronate) and ralox-
ifene. Alendronate or risedronate would
be considered first choice and the history
of dyspepsia is not a contraindication. If
she did suffer from significant reflux or
hiatus hernia, alendronate or risedronate
once weekly may be an option.
Raloxifene requires further study of its
efficacy in reducing risk fracture at sites
other than the spine.
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